Annovis Bio, Inc. has published results in Biomolecules showing that its newly developed dihydrate crystal form of buntanetap, which contains two moles of water, retains essentially the same pharmacokinetic (absorption, clearance, metabolism) profile as its original anhydrous form in studies involving mice, dogs, and humans.
The company said that the original form has been used in all preclinical and clinical work to date, while the crystal form offers greater stability.
Annovis is now using the crystal form in its pivotal Phase 3 clinical trial for early Alzheimer’s disease in the United States, which is currently enrolling participants. The trial is designed to deliver symptomatic results in Fall 2026 and disease-modifying results in Fall 2027.
Annovis also claims that the new crystal form extends intellectual property protection covering the compound’s mechanism of action, therapeutic use, and combination therapies into the 2040s.
